Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New MRI technique aims to help surgeons remove more of a deadly brain tumor

NCT ID NCT06455189

Disease control Sponsor: Case Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This trial tests whether a new type of MRI, called MR fingerprinting, can better show where a glioblastoma (an aggressive brain tumor) has spread compared to standard MRI. The goal is to help surgeons remove more of the tumor safely. The study involves adults with suspected glioblastoma and will first check if the approach is safe and feasible.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MR fingerprinting-guided surgical resection
What this could lead to
If successful, this approach could help surgeons remove more tumor tissue during glioblastoma surgery, potentially delaying recurrence.
What could go wrong
This is a small, early-phase safety and feasibility study. The new MRI technique may not improve outcomes or could increase surgical risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Stage I: Inclusion criteria: * Age \> 18 * MR imaging findings suggestive of GB * Maximal tumor diameter greater than 3 cm * Ability to provide written informed consent * Ability to undergo MRI scan * Consideration for biopsy, subtotal or gross total resection. Exclusion Criteria: * Contraindications to MRI * Contraindication to surgical treatment * Prior treatment for glioblastoma Stage II: Inclusion Criteria: * Age \> 18 * MR imaging findings suggestive of GB * Maximal tumor diameter greater than 3 cm * Ability to provide written informed consent * Ability to undergo MRI scan * Lesions amenable to gross total resection * Presence of peritumoral FLAIR signal abnormality beyond the area of enhancement. Exclusion Criteria: * Inability to undergo MRI imaging * Participants undergoing only stereotactic biopsy or less than gross total resection * Participants undergoing LITT * Inability to consent for the study * Previously treated/ recurrent glioma.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain tumor Glioblastoma

Contacts and locations

Locations

  • University Hospitals Cleveland Medical Center, UH Department of Radiology, Case Comprehensive Cancer Center

    Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.